Physician profile
Mohammed A Arman
NPI 1043304116
$21,121.65
in general payments reported to CMS, 2019-2025
36 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $903 · 2021: $910 · 2022: $1,104 · 2023: $1,270 · 2024: $1,182 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,129 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,129.26 |
| Education | $138.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $13,290.30 | 2019 | |
| Abbvie INC. | $2,233.00 | 2019-2025 | Mavyret, Rinvoq, Linzess |
| Celgene Corporation | $806.77 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $614.86 | 2019-2025 | Entyvio |
| Pfizer INC. | $595.76 | 2019-2025 | |
| Janssen Biotech, INC. | $573.11 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.12 | 2019-2025 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $306.60 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $306.48 | 2019-2023 | |
| Ardelyx, INC. | $288.50 | 2022-2025 | Ibsrela |
| Apollo Endosurgery US INC | $287.85 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Regeneron Healthcare Solutions, INC. | $226.92 | 2022-2025 | Dupixent |
| Ambu INC. | $171.78 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $124.72 | 2019-2023 | Linzess |
| Aimmune Therapeutics, INC. | $77.36 | 2025 | Zenpep, Vowst |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $76.15 | 2025 | |
| Intercept Pharmaceuticals, INC. | $75.82 | 2019-2024 | Ocaliva |
| Boston Scientific Corporation | $67.19 | 2019-2023 | Axios |
| Ipsen Biopharmaceuticals, INC | $64.32 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $61.64 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $59.41 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $56.94 | 2021-2022 | |
| Braintree Laboratories, INC. | $53.32 | 2020 | |
| Lilly USA, LLC | $49.08 | 2025 | Omvoh |
| Qol Medical, LLC | $41.99 | 2025 | Sucraid |
| Daiichi Sankyo INC. | $41.13 | 2022 | |
| Ucb, INC. | $38.82 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $38.25 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $31.80 | 2025 | Adalimumab-Aacf |
| E.R. Squibb & Sons, L.L.C. | $27.72 | 2024 | |
| Merck Sharp & Dohme LLC | $23.07 | 2022 | |
| Amgen INC. | $20.00 | 2025 | Uplizna |
| Phathom Pharmaceuticals, INC. | $15.00 | 2025 | Voquezna |
| Allergan, INC. | $14.78 | 2020 | |
| Shionogi INC | $14.32 | 2019 | |
| W. L. Gore & Associates, INC. | $12.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Arman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.